Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Ordinary shares, par value 0.002 GBP per share
-
Shares outstanding
-
147M
-
Number of holders
-
130
-
Total 13F shares, excl. options
-
125M
-
Shares change
-
+481K
-
Total reported value, excl. options
-
$1.8B
-
Value change
-
-$6.44M
-
Put/Call ratio
-
5.01
-
Number of buys
-
73
-
Number of sells
-
-52
-
Price
-
$14.38
Significant Holders of Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) as of Q1 2025
157 filings reported holding CNTA - Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share as of Q1 2025.
Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) has 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 125M shares
of 147M outstanding shares and own 85.15% of the company stock.
Largest 10 shareholders include Medicxi Ventures Management (Jersey) Ltd (20M shares), Index Venture Life Associates VI Ltd (9.96M shares), GENERAL ATLANTIC, L.P. (9.68M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (6.95M shares), JANUS HENDERSON GROUP PLC (5.92M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.34M shares), First Light Asset Management, LLC (4.87M shares), FARALLON CAPITAL MANAGEMENT LLC (4.33M shares), Avoro Capital Advisors LLC (4.05M shares), and FMR LLC (3.83M shares).
This table shows the top 130 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.